LUGPA VL

Genetic Evaluation of Hereditary Prostate Cancer - Sanjeev Kaul

Details
(Length of Presentation: 27 min) Sanjeev Kaul discusses hereditary prostate cancer (HPC) and why HPC is important, which patients should be tested based on the NCCN guidelines and what tests are available. Also, presented is the process for clinic testing for HPC and the future directions in this field. Biography: Sanjeev Kaul, MD, M.CH, Comprehensive Urology, Associate Professor of Urology, Oakla...

Practice Changing Applications of Radiology and Nuclear Medicine in GU Malignancies- Phillip Koo

Details
Phillip Koo presents practice changing applications of radiology and nuclear medicine in genitourinary malignancies in this lecture. He reviews the disruption in radiology specifically, imaging modalities, teleradiology, and artificial intelligence including the impact these have on patient care. Biography: Phillip J. Koo, MD , is the Division Chief of Diagnostic Imaging at the Banner MD Anderson...

Is There an Optimal TURBT Technique and the Color War? - Ashish Kamat

Details
Ashish Kamat discusses the importance of TURBT and its value for diagnosis, therapeutic and prognostic purposes as an essential part of multidisciplinary care with specific regards to clinical trials. Ashish also compares different agents for the detection of bladder cancer and how these agents are reflected in the AUA/SUO Guidelines. Biography: Ashish Kamat, MD, MBBS , is a Professor of Urology a...

Technologies Related to Prostate Biopsies - David Crawford

Details
(Length of Presentation: 19 min) David Crawford shares his perspective related to innovation in technology and the impact on medicine and clinical practice. His primary focus for review is prostate biopsies and the variety of influencers such as PSA, genomics, fusion biopsies, transrectal and micro-ultrasounds, D mapping, and electronic medical recording. Biography: E. David Crawford, MD, Professo...

When BCG Fails… Know All the Options - Gary Steinberg

Details
When BCG Fails… Know All the Options Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of Presentation: 32 min) Gary Steinberg, MD overviews the history of BCG since the 1980’s and it being the chosen method of treatment regardless if the patient has low, intermediate or high risk disease. He highlights the number of patients receiving BCG, and maintenance is the same and his...

Practice Changing Events in Prostate Cancer- Charles Ryan

Details
Practice Changing Events in Prostate Cancer, a Conversation with Alicia Morgans and Charles Ryan Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of Discussion: 14 min) Alicia Morgans, MD sits down with Charles Ryan, MD to discuss some of the practice changing events in prostate cancer and advanced prostate cancer in 2017. Some of the highlights they cover are the LATITUDE an...

Advanced Bladder Cancer Management: Immunotherapy - Interview with Arjun Balar

Details
Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence, an Interview with Alicia Morgans and Arjun Balar Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of Discussion: 13 min) Alicia Morgans, MD interviews Dr. Arjun Balar on his take home message on Advanced Bladder Cancer Management: Immunotherapy - Establishing a Clinic of Excellence, the t...

Imaging Controversies in Prostate Cancer- Interview with Phillip Koo

Details
Imaging Controversies for Assessing Localized and Advanced PCa, an Interview with Charles Ryan and Phillip Koo Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of interview: 6 min) Dr. Phillip Koo talks with Charles Ryan, MD about imaging controversies when it comes to local and metastatic disease. He overviews his LUGPA 2017 presentation on local disease in a practical and c...

Genomic Testing and Hereditary Prostate Cancer- Interview with Leonard Gomella

Details
Dr. Leonard Gomella gives Charles Ryan, MD an overview of the current state of the rapidly evolving field of genetic and genomic testing for prostate cancer. He highlights the movement from somatic changes in the tumor and into inherited risk and guidelines for the urologist to approach the prostate cancer patients with this concern. Additional Related Content: Watch: Dr. Leonard Gomella's present...

Chemotherapy in Prostate Cancer: Why, When and How?-Interview with Fred Saad

Details
Chemotherapy in Prostate Cancer: Why, When and How? - Presentation Highlights, an Interview with Alicia Morgans and Fred Saad Presentation from the 2017 annual LUGPA meeting in Chicago, IL (Length of interview: 11 min) In this interview with Alicia Morgans, Fred Saad provides insight into the role of chemotherapy today when treating prostate cancer. There are many drugs now available that are non-...